ArticleIndian journal of psychiatry2026
Clinical practice guidelines for the management of bipolar disorder: 2025 update.
Article in Indian journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Indian Psychiatric Society has previously published guidelines for the management of bipolar disorder (BD) in adults (2017) and children and adolescents (2019). The present guideline summarizes the major advancements in the management of BD since these publications. To make the guideline handier for the clinical practitioner, we have made several structural changes compared to the 2017 guideline. First: we have adopted a phase-specific approach with different sections and management algorithms for each major phase of BD (mania, depression, and mixed episodes in bipolar type I disorder [BD-I] and depression in bipolar type II disorder [BD-II]). Second: for better clarity and ease of adoption, we have structured our suggestions into first, second, and third-line treatments; these rankings are based on the composite of evidence, experience, and consensus ratings of efficacy, tolerability, availability, and affordability. Third: a separate section for BD-II disorder has been added, given its relatively high prevalence in the Indian setting. Fourth: we have added a detailed section on special treatment considerations, where practical issues such as the management of comorbidities, treatment adherence, the role of polypharmacy, clozapine, emerging treatments, and long-acting injectables, as well as the reproductive safety of medications in BD, are discussed. Finally, we have added an expert consensus section where we present our consensus opinions on common dilemmas in the management of BD. We liberally use tables and flowcharts to enhance understanding and uptake of the suggestions offered. We hope these guidelines promote evidence-informed decision-making in the management of BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.